2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

RD cells

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0043
    Ginsenoside Rd
    1 Publications Verification

    Gypenoside VIII

    		 NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca 2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd
  • HY-W016407
    Methyl 3,4-dihydroxyphenylacetate

    		Enterovirus Infection
    Methyl 3,4-dihydroxyphenylacetate is a potent enterovirus 71 (EV71) infection inhibitor. Methyl 3,4-dihydroxyphenylacetate inhibits EV71 replication in rhabdomyosarcoma (RD) cells .
    Methyl 3,4-dihydroxyphenylacetate
  • HY-W019806
    Lacto-N-fucopentaose I

    LNFP I

    		 Endogenous Metabolite CDK Reactive Oxygen Species (ROS) Apoptosis Enterovirus Bacterial Infection Inflammation/Immunology
    Lacto-N-fucopentaose I (LNFPI) is a human milk oligosaccharide (HMO), possessing antiviral and antibacterial activity. Lacto-N-fucopentaose I can reduce capsid protein VP1 to block virus adsorption, promote CDK2 and reduce cyclin E to recover cell cycle S phase block. Lacto-N-fucopentaose I inhibits ROS production and apoptosis in virus-infected cells. Lacto-N-fucopentaose I can also regulate intestinal microbiota to affect immune system development .
    Lacto-N-fucopentaose I
  • HY-14925
    Lapaquistat
    1 Publications Verification

    T-91485

    		 Endogenous Metabolite Drug Metabolite Metabolic Disease
    Lapaquistat (T-91485), a cholesterol biosynthesis inhibitor, is the active metabolite of Lapaquistat acetate (HY-16274). Lapaquistat can decrease statin-induced myotoxicity in lipid-lowering therapy .
    Lapaquistat
  • HY-136913
    (Rac)-Rhododendrol

    (Rac)-Betuligenol

    		 Endogenous Metabolite Inflammation/Immunology
    (Rac)-Rhododendrol ((Rac)-Betuligenol) is an aromatic compound with pro-oxidant activity. (Rac)-Rhododendrol may be useful in the suppression of liver diseases. (Rac)-Rhododendrol can be toxic to melanocytes, leading to cell death. The metabolite of (Rac)-Rhododendrol, RD-quinone, is cytotoxic and causes enzyme inactivation and endoplasmic reticulum stress by binding to thiol proteins. (Rac)-Rhododendrol-derived melanin exhibits potent pro-oxidant activity and may cause oxidative stress .
    (Rac)-Rhododendrol
  • HY-162715
    EV-A71-IN-2

    		Enterovirus Infection
    EV-A71-IN-2 (compound 6c) is a anti-EV-A71 agent with the EC50 values of 0.29 μM and 1.66 μM aganist of EV-A71-MRC-5 cells and EV-A71-RD cells, respectively. EV-A71-IN-2 can be used for study of enterovirus infection .
    EV-A71-IN-2
  • HY-N0043R
    Ginsenoside Rd (Standard)

    Gypenoside VIII (StandaRD)

    		 Reference Standards NF-κB COX Calcium Channel Cytochrome P450 Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    Ginsenoside Rd (Standard) is the analytical standard of Ginsenoside Rd. This product is intended for research and analytical applications. Ginsenoside Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Ginsenoside Rd inhibits expression of COX-2 and iNOS mRNA. Ginsenoside Rd also inhibits Ca2+ influx. Ginsenoside Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
    Ginsenoside Rd (Standard)
  • HY-174402
    PLpro-IN-9

    		SARS-CoV Infection
    PLpro-IN-9 (Compound 14e) is a SARS-CoV-2 PLpro inhibitor with an IC50 of 12.0 μM and a KD of 1.86 μM. PLpro-IN-9 has low cytotoxicity but poor metabolic stability. PLpro-IN-9 can be used in the research of SARS-CoV-2 .
    PLpro-IN-9
  • HY-161687
    Cisplatin/Dasatinib prodrug-1

    		Src Cancer
    Cisplatin/Dasatinib prodrug-1 (Compound 3) is a prodrug of Cisplatin (HY-17394) and Dasatinib (HY-10181). Cisplatin/Dasatinib prodrug-1 exhibits antiproliferative activity against A2780, MDA-MB-231, MCF7, HCT116, RD, Thp1 and HL60 cancer cells with IC50s of 0.1, 0.1, 0.36, 2.0, 0.4, 0.3 and 0.25 μM, respectively .
    Cisplatin/Dasatinib prodrug-1
  • HY-175740
    Antiviral agent 71

    		Enterovirus Infection
    Antiviral agent 71 (Compound 26) is an antiviral agent. Antiviral agent 71 has a broad-spectrum enterovirus antiviral activity, such as EV-D68, Echo-11 and HRV-14 with EC50s of 0.017-4.1 μM. EV-D68-IN-1 can be used for non-polio enteroviruses (NPEV) infections research .
    Antiviral agent 71
  • HY-175671
    LSD1/HDAC-IN-3

    		HDAC Histone Demethylase Neurological Disease
    LSD1/HDAC-IN-3 is a inhibitor targeting class I HDAC and LSD1 enzymes. LSD1/HDAC-IN-3 inhibits HDAC1, HDAC2, HDAC3, and LSD1 with IC50 values of 1702 nM, 842 nM, 358 nM, and 1074 nM, respectively. LSD1/HDAC-IN-3 exhibits antioxidant effects in H2O2-stressed ARPE-19 and 661W retinal cells, increasing levels of acetylated and methylated histone H3. LSD1/HDAC-IN-3 enhances photoreceptor survival in the rd10 mouse model of retinitis pigmentosa. LSD1/HDAC-IN-3 can be used for the study of inherited retinal diseases such as retinitis pigmentosa (RP) .
    LSD1/HDAC-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: